Please login to the form below

Not currently logged in
Email:
Password:

melanoma drug

This page shows the latest melanoma drug news and features for those working in and with pharma, biotech and healthcare.

Roche’s Tecentriq combo scores FDA approval for melanoma

Roche’s Tecentriq combo scores FDA approval for melanoma

The FDA approval of this Tecentriq combination represents an important step forward for many patients living with advanced melanoma," he added. ... In fact, Keytruda was first approved for advanced melanoma back in September 2014, when it became the

Latest news

  • BMS’ Opdivo/Yervoy combination fails to shine in melanoma BMS’ Opdivo/Yervoy combination fails to shine in melanoma

    It seems that this principle does not extend across all cancer types, with this stumble in melanoma a clear example of that. ... advanced stage melanoma who received the drug along with surgery.

  • Scancell preps phase 2 challenge for melanoma vaccine Scancell preps phase 2 challenge for melanoma vaccine

    Progress continues for biotech. Scancell says it is just weeks away from enrolling patients into its phase 2 trial of melanoma drug SCIB1, its lead T-cell boosting immunotherapy, in the ... The drug has already been through a phase 1/2 trial in around 35

  • NICE turns down Opdivo for adjuvant melanoma therapy NICE turns down Opdivo for adjuvant melanoma therapy

    BMS drug currently only licensed treatment in this setting. Bristol-Myers Squibb’s efforts to push the use of Opdivo earlier in the course of melanoma treatment have hit a snag ... surveillance, which is usual current management for completely resected

  • Keytruda is first I-O drug cleared for melanoma in China Keytruda is first I-O drug cleared for melanoma in China

    The approval by the China National Drug Administration (CNDA) is for adults with unresectable or metastatic melanoma following failure of one prior line of therapy, and ends a drought in effective ... With the approval of pembrolizumab in China, the

  • BMS' Yervoy picks up another indication in Europe BMS' Yervoy picks up another indication in Europe

    The EU green light will be welcomed news after BMS saw the big-selling melanoma drug flop in a head-to-head trial with Merck &Co’s Keytruda (pembrolizumab), which was ... melanoma is an outcome of BMS’s unyielding commitment to advancing treatments

More from news
Approximately 2 fully matching, plus 71 partially matching documents found.

Latest Intelligence

  • Cancer immunotherapy: What's on the horizon? Cancer immunotherapy: What's on the horizon?

    But there are downsides too. It’s worth noting that Roche’s BRAF-targeting drug Zelboraf (vemurafenib) for melanoma has seen mixed results in other tumours, suggesting that ‘histologic context’ – ie ... While use of Imlygic has been limited,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest appointments

  • Chris Bowden joins Agios Chris Bowden joins Agios

    During this time he worked on major cancer medicines, such as melanoma drug Zelboraf (vemurafenib) and Erivedge (vismodegib) for patients with unresectable, locally advanced or metastatic basal cell carcinoma.

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Spirit, an OPEN Health Company

We find the soul in the science, the humanity in the data, harnessing the power of creativity to deliver medical...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....